This product is formulated for professional aesthetic applications requiring both immediate mechanical support and longer-term tissue remodeling.
Conventional hyaluronic acid fillers provide immediate volume correction through an extracellular gel matrix, but undergo enzymatic degradation over several months. Standalone poly-L-lactic acid (PLLA) stimulators provide gradual collagen induction via localized macrophage and fibroblast activation, but offer limited immediate volume post-injection.
Material Characteristics & Functional Synergy
|
Component |
Material Type |
Primary Function |
Clinical Role |
|
Hyaluronic Acid (HA) |
Biosynthetic, Cross-linked Polysaccharide |
Immediate viscoelastic gel matrix |
Initial volumization, tissue displacement, and immediate structural correction. |
|
Poly-L-lactic Acid (PLLA) |
Biodegradable Synthetic Polymer |
Particulate biostimulatory scaffold |
Progressive fibroblast recruitment, collagen synthesis, and long-term structural remodeling. |
|
Composite System |
Dual-Phase Suspension / Matrix |
Integrated immediate support + sustained regeneration |
Bridges the performance gap between traditional volume fillers and standalone biostimulators. |
Technical Specifications
|
Technical Parameter |
Specification Standard |
|
Product Name |
PLLA HA Composite Dermal Filler |
|
PLLA Content |
Configured per technical dossier |
|
HA Concentration |
Configured per technical dossier |
|
HA Cross-linking Agent |
BDDE (Controlled residual limit < 2 ppm) |
|
PLLA Particle Morphology |
Porous, spheroidal microparticles |
|
PLLA Particle Size Distribution (D50) |
Controlled micron range |
|
Carrier / Suspension Medium |
Sterile water for injection / carboxymethylcellulose / mannitol buffer system |
|
Product Volume / Fill Weight |
1.0 mL / 2.0 mL pre-filled syringe or lyophilized vial configuration |
|
pH Range |
6.8 - 7.4 |
|
Osmolality |
280 - 320 mOsm/kg |
|
Rheological Properties (Storage Modulus G') |
Optimized for mid-dermal to subcutaneous elasticity |
|
Extrusion Force |
Verified for smooth delivery via recommended needle gauge |
|
Sterilization Method |
Terminal sterilization (Ethylene Oxide or Aseptic Processing) |
|
Bacterial Endotoxin |
< 0.5 EU/mL (Complying with ISO standards) |
|
Recommended Injection Tool |
27G / 30G needle or appropriate micro-cannula |
|
Shelf Life |
24 months from date of manufacture |
|
Storage Conditions |
Store at controlled room temperature (15°C - 25°C), protect from freezing and direct sunlight |
|
Regulatory Support |
ISO 13485 manufacturing compliance, technical file, CoA, and biocompatibility test reports available |
Intended Application Areas
The product is engineered for professional aesthetic administration targeting structural tissue depletion and contour defects, subject to approved regional indications and clinician training.
Mid-Face Volume Restoration: Correction of age-related subcutaneous fat depletion and malar volumetric loss.
Nasolabial Folds & Marionette Lines: Structural support for moderate-to-severe facial wrinkles and folds.
Temporal Hollowing: Restoration of temporal contour symmetry and upper facial balance.
Jawline & Chin Contouring: Definition of the mandibular border and structural projection of the chin.
Skin Dermal Matrix Support: Improvement of localized skin elasticity and structural firmness through dual-phase action.
Manufacturing & Quality Control Protocols
Consistency in a composite injectable requires precise control over raw material purity, microsphere morphology, and phase dispersion stability.
Raw Material Verification
Incoming polymer and polysaccharide batches undergo identity verification via FTIR, purity assays via HPLC, and microbiological burden testing.
Strict supplier qualification ensuring full traceability of raw material lots.
PLLA Microsphere Control
Laser diffraction particle sizing to verify strict thresholds, preventing oversized particles that cause needle clogging or micro-embolization risks.
Scanning electron microscopy (SEM) analysis to confirm smooth, uniform microsphere surface morphology.
HA Matrix & Gel Rheology
Monitoring of molecular weight distribution, degree of cross-linking, and residual cross-linking agent limits.
Rotational rheometry testing to verify storage modulus, loss modulus, and complex viscosity under physiological stress.
Finished Product Testing
Aseptic processing and terminal sterilization validation under cleanroom manufacturing standards.
Batch release testing covering sterility, bacterial endotoxins, particulate matter, pH, osmolality, and syringe extrusion force uniformity.
OEM, ODM & Private Label Capabilities
Comprehensive manufacturing infrastructure supports customized product development for international medical aesthetic brands, clinic groups, and regional distributors.
Customization Parameters:
Formulation & Concentration: Tailored PLLA content, HA molecular weights, and carrier compositions.
Delivery Format: Pre-filled glass syringes or sterile dual-chamber/vial configurations.
Packaging & Branding: Private-label outer carton design, custom logo stamping, localized IFU printing, and unique serialization.
Accessory Integration: Custom bundling with matched needles or micro-cannulas.
FAQ
Q: What is the primary difference between a standalone PLLA product and a PLLA HA composite?
A: A standalone PLLA product relies exclusively on microparticles that require hydration and trigger a delayed cellular response for volume generation, offering minimal immediate correction. A composite formulation includes an HA gel carrier that provides immediate structural volume upon injection, while the suspended PLLA particles initiate progressive, long-term collagen synthesis concurrently.
Q: How is needle clogging prevented during the injection of PLLA microspheres?
A: Needle blockage is prevented through strict control of particle size distribution, elimination of oversized aggregates during manufacturing, and optimized dispersion uniformity within the carrier fluid, allowing smooth passage through fine-gauge medical needles or cannulas.
Q: What storage conditions are required for the product?
A: The product should be stored at controlled room temperature, protected from extreme temperature fluctuations, moisture, and direct ultraviolet light. Specific storage thresholds are detailed on the product label and controlled technical specification sheet.
Q: Can the formulation ratio of PLLA to HA be adjusted for OEM projects?
A: Yes. Custom formulation adjustments regarding PLLA concentration, HA molecular weight, and total fill volume can be evaluated during the technical feasibility review phase for qualified OEM and private-label partners.
Q: What documentation is supplied with each commercial shipment?
A: Each commercial shipment is accompanied by a Certificate of Analysis detailing lot-specific test results for sterility, endotoxins, pH, osmolality, and physical appearance, alongside standard shipping and customs clearance documentation.
Hot Tags: plla ha composite dermal filler, China plla ha composite dermal filler manufacturers, suppliers, factory
